Ewelina Lachowska

Ewelina Lachowska

Auto-generated profile, based on publicly available information

Ewelina Lachowska

Provincial Specialist Hospital in Wrocław

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 June 2026 in Quality in Sport
Verified
Journal Article
Open access
PDF file
MCMateusz Chmiela
Mateusz Chmiela
WBWojciech Przemysław Baran
Wojciech Przemysław Baran
PBPatrycja Anna Bartkiewicz
Patrycja Anna Bartkiewicz
AŚAda Świątko
Ada Świątko
TJTomasz Wiktor Jędrasek
Tomasz Wiktor Jędrasek
ATAntonina Trzaskoma
Antonina Trzaskoma
Introduction: In recent years, bigorexia has gained increasing attention as a mental health issue closely linked to the rise of contemporary fitness culture promoting extreme muscularity, reduced body fat, and appearance-oriented lifestyles. The condition involves a distorted perception of one’s physique, accompanied by a persistent belief of being inadequately muscular despite often having a well-developed body. Aim: This review aimed to summarize and critically discuss current findings on bigorexia, focusing on its epidemiology, contributing risk factors, symptomatology, diagnostic challenges, and available treatment strategies. Review findings: Bigorexia predominantly affects individuals participating in bodybuilding and other strength-focused activities, especially men, although emerging evidence suggests that women may also be affected more frequently than previously recognized. The disorder is frequently overlooked in clinical practice, partly because its symptoms overlap with other psychiatric conditions such as depressive disorders, anxiety disorders, eating disorders, and occasionally psychotic spectrum disorders. Accurate differential diagnosis is therefore crucial. Although evidence regarding treatment remains limited, psychotherapy constitutes the cornerstone of management, with cognitive-behavioral therapy demonstrating the greatest effectiveness. In some patients, pharmacological support may additionally be considered. Conclusions: Greater awareness of bigorexia among clinicians and society is necessary to facilitate earlier identification and more effective intervention. Additional research is needed to better define the disorder, clarify gender-related differences, and develop evidence-based therapeutic approaches.

17 July 2026 in Journal of Education, Health and Sport
Verified
Journal Article
Open access
PDF file
PBPatrycja Anna Bartkiewicz
Patrycja Anna Bartkiewicz
WBWojciech Przemysław Baran
Wojciech Przemysław Baran
AŚAda Świątko
Ada Świątko
TJTomasz Wiktor Jędrasek
Tomasz Wiktor Jędrasek
ELEwelina Lachowska
Ewelina Lachowska
MCMateusz Chmiela
Mateusz Chmiela
Introduction: Hypercholesterolemia is a leading cardiovascular risk factor with a global prevalence of approximately 24%, contributing substantially to atherosclerotic disease. Despite the well-established efficacy of statins and other pharmacological agents, adherence remains a challenge due to adverse effects and patient reluctance toward conventional therapy. Purpose: This narrative review synthesizes current evidence on the lipid-modulating properties of seven herbal products and nutraceuticals: garlic, green tea, guggul, red yeast rice, fenugreek, artichoke, and berberine. It focuses on their mechanisms of action, clinical efficacy, and safety profiles. Current knowledge: The reviewed compounds exhibit diverse lipid-lowering mechanisms, including HMG-CoA reductase inhibition, LDL receptor upregulation, reduced intestinal cholesterol absorption, and enhanced bile acid excretion. Red yeast rice, owing to its lovastatin content, holds the strongest clinical evidence, achieving LDL-C reductions of 15-34%. Berberine and artichoke leaf extract also show consistent lipid-lowering effects. Evidence for garlic, green tea, and fenugreek is promising but heterogeneous. Guggul data remain conflicting, with some trials reporting adverse lipid outcomes. Conclusions: These nutraceuticals may serve as adjunctive interventions alongside lifestyle modification in selected patients but cannot replace established pharmacotherapy. Large-scale, standardized randomized controlled trials are needed to confirm their efficacy and long-term safety.

13 October 2026 in Roczniki Psychologiczne
Verified
Journal Article
Open access
PDF file
PBPatrycja Bartkiewicz
Patrycja Bartkiewicz
WBWojciech Baran
Wojciech Baran
ELEwelina Lachowska
Ewelina Lachowska
An increasing number of studies have examined the effects of psychedelics on mental wellbeing and their potential use as adjunctive therapy for depressive and anxiety disorders. In this review, we compiled research from the past ten years that focused specifically on the impact of psychedelic use on personality traits. A systematic search was conducted across the databases Web of Science, PubMed, and Scopus, as well as the trial registry ClinicalTrials.gov, identifying a total of 27 studies including a total of 1,941 participants. The findings from these studies are heterogeneous; however, majority of them report that psychedelics may induce changes in personality traits associated with improvements in mental health, particularly reductions in neuroticism. Adaptive changes appear to be influenced by baseline participant characteristics, including personality traits, as well as qualitative aspects of the psychedelic experience itself. The current evidence is limited, as most studies involved small sample sizes, highlighting the need for more randomized, double-blind controlled trials to draw definitive conclusions. Future research would also benefit from focusing on psychedelic-naïve participants to better understand the effects in individuals without prior exposure. Overall, while preliminary findings are promising, rigorous and larger-scale investigations are essential to clarify the mechanisms and long-term impact of psychedelics on personality and psychological wellbeing.

17 March 2026 in Journal of Education, Health and Sport
Verified
Journal Article
Open access
PDF file
WBWojciech Baran
Wojciech Baran
PBPatrycja Bartkiewicz
Patrycja Bartkiewicz
ELEwelina Lachowska
Ewelina Lachowska
TJTomasz Wiktor Jędrasek
Tomasz Wiktor Jędrasek
AKAdrian Korman
Adrian Korman
WAWafa Al-Batool
Wafa Al-Batool
Background. Kratom (Mitragyna speciosa) use is increasing internationally and case reports describe a range of withdrawal syndromes. Clinical guidance for recognizing and managing kratom withdrawal is limited. This narrative review of case reports synthesizes clinical features, management strategies, and outcomes among published patient cases. Aim. To characterize the clinical features, management strategies, and outcomes reported in published cases of kratom withdrawal. Additionally, identify common patterns in presentation and treatment that may inform preliminary clinical guidance for recognition and management. Methods. Article databases were searched for case studies related to kratom withdrawal. After screening titles/abstracts and full texts, 12 reports describing 16 individual patients were included. Data was extracted and findings were narratively synthesized across demographics/use characteristics, clinical presentation, pharmacological management, and outcomes. Results. Reported reasons for kratom use included self-treatment of opioid use disorder, pain, and psychiatric symptoms. Presentation varied from mild autonomic and gastrointestinal symptoms to severe, atypical syndromes. Opioid-like features of mild severity relative to usual opioid use predominated. Pharmacological management most commonly involved buprenorphine/naloxone. Clonidine and benzodiazepines were common adjuncts. Conclusions. Case-level evidence and existing literature indicates that kratom withdrawal most often presents as an opioid-like syndrome and that buprenorphine, with symptom-driven, conservative induction, was the most consistently effective treatment in reported cases. Interpretation is limited by small numbers, heterogeneous and incomplete reporting (dose/formulation/duration). Prospective, standardized reporting of exposure and outcomes and kratom-specific validation of withdrawal assessment tools are needed to inform evidence-based management.

22 July 2026 in Quality in Sport
Verified
Journal Article
Open access
PDF file
MCMateusz Chmiela
Mateusz Chmiela
ELEwelina Maria Lachowska
Ewelina Maria Lachowska
PBPatrycja Anna Bartkiewicz
Patrycja Anna Bartkiewicz
WBWojciech Przemysław Baran
Wojciech Przemysław Baran
CJCyprian Mariusz Janiszewski
Cyprian Mariusz Janiszewski
OROskar Ratajczyk
Oskar Ratajczyk
Background: Music Performance Anxiety is a frequent problem among musicians. Beta-blockers, especially propranolol, are used by some performers to reduce somatic symptoms of stage fright. Aim: This narrative review aimed to analyse the mechanisms, clinical evidence, prevalence, safety and ethical implications of beta-blocker use among musicians, including parallels with anti-doping regulation in precision sports. Material and methods: A targeted literature search was conducted using PubMed, Google Scholar, JSTOR and ResearchGate. Clinical studies, surveys, reviews, regulatory documents and bioethical analyses concerning beta-blockers, Music Performance Anxiety, stage fright and performance enhancement were included. Results: Beta-blockers may reduce peripheral manifestations of sympathetic arousal and may be useful in selected performance situations. However, the available evidence remains limited by small samples, older study designs and heterogeneous outcome measures. Survey data indicate that beta-blocker use occurs among musicians, particularly in auditions and other high-pressure performances. Their use also raises safety concerns and ethical questions about the boundary between therapy, symptom control and performance enhancement. Conclusions: The available evidence suggests that beta-blockers may have a limited role in selected musicians, mainly as a short-term option for reducing somatic symptoms of stage fright. They should not be seen as a routine or complete treatment for Music Performance Anxiety. Their use, particularly before auditions and other high-pressure situations, raises questions about safety, medical supervision and fairness. The parallel with precision sports, where beta-blockers are formally regulated, further highlights the ethical complexity of their use in music. Therefore, beta-blocker use in musicians should be approached cautiously, with clear education and individual medical assessment.

10 August 2026 in Quality in Sport
Verified
Journal Article
Open access
PDF file
WBWojciech Baran
Wojciech Baran
ELEwelina Lachowska
Ewelina Lachowska
CJCyprian Mariusz Janiszewski
Cyprian Mariusz Janiszewski
PBPatrycja Bartkiewicz
Patrycja Bartkiewicz
Background: Large ranges of movement are important in dance, especially in demanding choreography. Joint hypermobility is common among dancers, but its interpretation is complex, as increased mobility may relate to both performance demands and health concerns. Aim: This narrative review summarizes current evidence on joint hypermobility in dancers, focusing on assessment methods, prevalence, performance-related aspects, musculoskeletal and functional consequences, and management considerations. Material and methods: A targeted literature search used terms related to joint hypermobility, generalized joint hypermobility, Beighton Score, dance, ballet, contemporary dance, injuries, pain, fatigue, balance, and physical fitness. Original quantitative and qualitative studies, prospective cohorts, randomized controlled trials, reviews, and relevant background papers were included. Results: Prevalence of joint hypermobility in dancers varies substantially depending on population, assessment tool, and cut-off used, but appears common and possibly more frequent than in non-dancers. Hypermobility may offer aesthetic and choreographic value, yet is also linked to arthralgia, instability-related injuries, fatigue, reduced physical fitness, and psychological distress. Direct evidence on management in hypermobile dancers is limited, though broader rehabilitation literature suggests exercise-based interventions may improve pain, proprioception, quality of life, and function in symptomatic cases. Conclusions: Joint hypermobility in dancers is neither purely beneficial nor purely harmful, but a performance-related trait with variable consequences. Management is mainly relevant when hypermobility is symptomatic. Future research should use consistent definitions and cut-offs, distinguish asymptomatic from symptomatic hypermobility, and evaluate dance-specific management strategies.